SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
Phase 2
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: SH229 tablets
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT04070235
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Jiangsu, China
A Food-Effect Study of SHC014748M in Healthy Subjects
Phase 1
- Conditions
- Healthy Volunteer
- Interventions
- Drug: SHC014748M Capsules
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04006860
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions
Phase 1
- Conditions
- Healthy Volunteer
- Interventions
- Drug: SH-1028 Tablets
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03973632
A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT03823807
A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Interactions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03748745
- Locations
- 🇨🇳
Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China
Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03618043
- Locations
- 🇨🇳
Shanghai east hospital, Shanghai, China
Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT03603262
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03588923
- Locations
- 🇨🇳
Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, Jilin, China
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
Phase 1
- Conditions
- Small Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)B-Cell Non-Hodgkin Lymphomas(NHL)
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03588598
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath